Cost Of Revenue - Nektar Therapeutics (NASDAQ:NKTR) - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 1.815 USD -0.82%

Updated:

Nektar Therapeutics
Cost of Revenue

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

|

Adjust for Inflation

Nektar Therapeutics
Cost of Revenue Peer Comparison

JNJ

BMY

PFE

MRK

LLY

Company		Cost of Revenue	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Nektar Therapeutics NASDAQ:NKTR	Cost of Revenue -$35.2m	CAGR 3-Years -18%	CAGR 5-Years -9%	CAGR 10-Years 0%
	Johnson & Johnson NYSE:JNJ	Cost of Revenue -$26.1B	CAGR 3-Years 3%	CAGR 5-Years 1%	CAGR 10-Years -2%
	Bristol-Myers Squibb Co NYSE:BMY	Cost of Revenue -$11B	CAGR 3-Years -3%	CAGR 5-Years -10%	CAGR 10-Years -9%
	Pfizer Inc NYSE:PFE	Cost of Revenue -$16.3B	CAGR 3-Years -57%	CAGR 5-Years N/A	CAGR 10-Years -6%
	Merck & Co Inc NYSE:MRK	Cost of Revenue -$15.4B	CAGR 3-Years -5%	CAGR 5-Years -4%	CAGR 10-Years 1%
	Eli Lilly and Co NYSE:LLY	Cost of Revenue -$7.1B	CAGR 3-Years -5%	CAGR 5-Years -9%	CAGR 10-Years -4%

See Also

Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Cost of Revenue amounts to -35.2m USD.

Over the last year, the Cost of Revenue growth was -51%. The average annual Cost of Revenue growth rates for Nektar Therapeutics have been -18% over the past three years , -9% over the past five years .

Join more than 137,800+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.